AmerisourceBergen Comments on DEA’s Creation of Transparency Resource to Help Distributors Combat Opioid Abuse

11:15 EST 15 Feb 2018 | Businesswire

AmerisourceBergen, a global healthcare solutions leader, released the following comment regarding the announcement by the U.S. Drug Enforcement Administration (“DEA”) that it would add a new feature to its ARCOS Online Reporting System to enable manufacturers and distributors to view the number of competitors selling controlled substances to prospective customers within a six-month window:

“AmerisourceBergen supports yesterday’s actions by the DEA, which represent progress toward the goal we have promoted of achieving increased industry data transparency between the DEA, drug distributors and pharmacies. This is a step forward on the path to being able to more effectively collaborate to identify and stop nefarious actors within the pharmaceutical supply chain.

Distributors have long been individually required to report controlled substance data to DEA, and we will now be able to see how many of our peers within the industry are supplying opioid-based medicines to the same pharmacies we are. This should help distributors in detecting suspicious orders.

We strongly encourage DEA to build on yesterday's progress against opioid abuse in America, by allowing even greater access to additional ‘scrubbed’ and de-identified data so we can evaluate the full context of a particular pharmacy opioid order.”

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500, with more than $150 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at

AmerisourceBergen Corporation
Gabe Weissman
Group Vice President, Communications
610-727-3696 – Office
267-438-7998 – Mobile


More From BioPortfolio on "AmerisourceBergen Comments on DEA’s Creation of Transparency Resource to Help Distributors Combat Opioid Abuse"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...